Perspectives in Medicinal Chemistry
Synopsis: An open access, peer reviewed electronic journal that covers drug design in the form of commentaries and reviews which do not require disclosure of proprietary information.
Indexing: Pubmed, Pubmed Central, Embase, Google Scholar, CAS, DOAJ, OAIster
Processing time: Decision in 2 weeks for 90% of papers.
Latest news:
Small Family with Key Contacts: Par14 and Par17 Parvulin Proteins, Relatives of Pin1, Now Emerge in Biomedical Research
Jonathan W Mueller1 and Peter Bayer1
1Institute for Structural and Medicinal Biochemistry, Centre for Medical Biotechnology—ZMB, University of Duisburg-Essen, 45117 Essen, Germany.
Abstract
The parvulin-type peptidyl-prolyl cis/trans isomerase Pin1 is subject of intense biochemical and clinical research as it seems to be involved in the pathogenesis of certain cancers and protein folding illnesses like Alzheimer’s and Parkinson’s disease. In addition to Pin1, the human genome only contains a single other parvulin locus encoding two protein species—Par14 and Par17. Much less is known about these enzymes although their sequences are highly conserved in all metazoans. Parvulin has been proposed to function as Pin1 complementing enzyme in cell cycle regulation and in chromatin remodelling. Pharmaceutical modulation of Par14 might therefore have benefi ts for certain types of cancer. Moreover, the Par17 protein that has been shown to be confi ned to anthropoid primate species only might provide a deeper understanding for human-specifi c brain development. This review aims at stimulating further research on Par14 and Par17 that are overlooked drug targets in the shadow of an overwhelming plethora of Pin1 literature by summarising all current knowledge on these parvulin proteins.
Readers of this also read:
- Lunasin: A Novel Cancer Preventive Seed Peptide
- Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
- Bioactive and Structural Metabolites of Pseudomonas and Burkholderia Species Causal Agents of Cultivated Mushrooms Diseases
- Uncertainty Analysis of Drug Concentration in Pharmaceutical Mixtures
- Plasma Protein Profiles Differ Between Women Diagnosed with Cervical Intraepithelial Neoplasia (CIN) 1 and 3
- 26/May/2009
Aminoglycosides: Molecular Insights on the Recognition of RNA and Aminoglycoside Mimics
- 28/Apr/2009
Perspectives on Using Physcomitrella Patens as an Alternative Production Platform for Thapsigargin and Other Terpenoid Drug Candidates
- 04/Mar/2009
Bioactive and Structural Metabolites of Pseudomonas and Burkholderia Species Causal Agents of Cultivated Mushrooms Diseases
- 09/May/2008
The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy
- 10/Apr/2008
Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
- 10/Apr/2008
Lunasin: A Novel Cancer Preventive Seed Peptide
- 25/Mar/2008
Effects of FK506 on Ca2+ Release Channels (Review)
- 18/Mar/2008
Small Family with Key Contacts: Par14 and Par17 Parvulin Proteins, Relatives of Pin1, Now Emerge in Biomedical Research
- 07/Mar/2008
Modifications of Antiepileptic Drugs for Improved Tolerability and Efficacy
- 14/Feb/2008
Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
- 10/Feb/2008
The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer
- 18/Jan/2008
Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases
- 11/Dec/2007
Derivatives of 5-Aminolevulinic Acid for Photodynamic Therapy
- 11/Dec/2007
The pKa Distribution of Drugs: Application to Drug Discovery
- 17/Sep/2007
FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology
- 06/Sep/2007
Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034
- 26/Jun/2007